Relationship between uncoupling protein 1 (UCP1) levels and psoriasis

Santrauka

Background/aim: Psoriasis is an autoimmune, chronic and common skin disease. Comorbidities also increase the mortality risk of the disease. The aim of this study is to investigate the changes in UCP1 levels in psoriasis patients and to evaluate their possible role in the pathogenesis of the disease, focusing on disease severity (Psoriasis Area and Severity Index), dyslipidemia, inflammation and cardiovascular risk.Materials and methods: This study included 30 psoriasis patients and 30 healthy individuals as a control group. Serum UCP1 was measured using an ELISA test kit. The laboratory results of psoriasis patients and healthy controls were compared.Results: UCP1 level was a significant candidate marker for the prediction of psoriatic disease (AUC: 0.708, 95% CI: 0.577 – 0.819, p=0.002) with a sensitivity of 66.67%, specificity of 76.67%, NPV of 69.7% and PPV of 74.1%. A simple logistic regression analysis showed that a patient with a UCP1 value below 7.561 had a 73% (OR: 0.27, 95% CI: 0.08 – 0.94, p=0.039) lower probability of developing psoriasis than a patient with a UCP1 value above 7.561. Regarding the biochemical parameters, the hs-CRP and triglyceride levels of the patients were significantly higher compared to the healthy controls, while the HDL level was lower. Conclusion: According to the sensitivity (66.67%) and specificity (76.67%) of UCP1, UCP1 may be a valuable candidate marker in the diagnosis of psoriasis patients in the symptomatic/asymptomatic phase. Further work is needed to substantiate these ideas.